Genetically modified organisms underpin a surprisingly large share of modern medicine, from the insulin that millions of people inject daily to cancer treatments that reprogram a patient’s own immune cells. The first major medical GMO, a bacterium engineered to produce human insulin, reached the market in 1982, and the field has expanded rapidly since then into vaccines, gene therapies, transplant organs, diagnostic tools, and disease-carrying insect control. Many people who are skeptical of GMOs in food already depend on them in their medicine cabinet without realizing it.
Bacteria as Tiny Drug Factories
The oldest and most widespread medical use of GMOs is putting human genes into microorganisms so they churn out therapeutic proteins. The landmark case is insulin. Before the 1980s, people with diabetes relied on insulin extracted from pig and cow pancreases, which worked but sometimes triggered allergic reactions. Researchers solved this by inserting synthetic copies of the human insulin A and B chain genes into E. coli bacteria. Each bacterial strain produced one chain as part of a larger fused protein, which was then chemically cleaved and purified. The two chains were combined through a chemical bonding step, yielding insulin identical to what the human body makes.1PubMed Central. Making, Cloning, and the Expression of Human Insulin Genes in Bacteria: The Path to Humulin That product, Humulin, became the first recombinant DNA drug approved by the FDA and opened the floodgates for what the industry now calls “biologics.”
Today, genetically modified bacteria and yeast produce hundreds of medical proteins: clotting factors for hemophilia, human growth hormone, erythropoietin for anemia, and a wide range of monoclonal antibodies used in everything from cancer treatment to autoimmune disease management. Getting these microbes to fold complex proteins correctly remains a significant engineering challenge. Researchers use molecular helpers called chaperones, co-expressed alongside the target protein, to coax molecules like monoclonal antibodies into the right three-dimensional shape so they actually function.2PubMed. Molecular chaperones: A revolutionary approach for increased solubility of recombinant mAbs from bacterial and yeast systems Different host organisms have different strengths: E. coli tends to produce higher yields of antimicrobial proteins, while other bacterial species may be better suited for specific products.3PubMed Central. Recombinant production of antimicrobial proteins in bacterial expression systems: Escherichia coli vs. lactic acid bacteria
Recombinant Vaccines
One of the most common vaccines in the world owes its existence to genetic modification. The hepatitis B vaccine used globally since the late 1980s is made by inserting the gene for a hepatitis B surface protein into baker’s yeast (Saccharomyces cerevisiae). The yeast cells produce the viral protein, which is purified and formulated into a vaccine. Because the vaccine contains only the protein and no actual virus, it cannot cause infection. Early trials confirmed that this yeast-derived vaccine was safe and equally effective at stimulating immunity as the older plasma-derived version.4PubMed. Yeast recombinant hepatitis B vaccine The development of that antigen in yeast was a collaborative effort that proved recombinant vaccines could work in animals and humans alike.5PubMed. Human hepatitis B vaccine from recombinant yeast The same basic approach now powers vaccines against HPV (the Gardasil series) and the protein-based COVID-19 vaccine from Novavax.
A different strategy uses genetically modified viruses as delivery vehicles. Adenovirus-vector vaccines strip a common cold virus of its ability to replicate, then insert a gene encoding a target pathogen’s protein. When injected, the modified virus enters your cells, which read the inserted gene and produce the foreign protein, training your immune system to recognize it. Adenovirus vectors are attractive because they transduce cells efficiently, can accommodate reasonably large gene inserts, and trigger a useful level of innate immune activation on their own.6PubMed Central. Adenovirus vector-based vaccine for infectious diseases This platform was used in the Oxford-AstraZeneca and Johnson & Johnson COVID-19 vaccines and in approved Ebola vaccines. Researchers continue to explore adenoviral vectors for diseases like HIV and respiratory syncytial virus.7Molecular Therapy. Recent Advances in Adenoviral-Based Vaccines and Their Use in Mucosal Immunization
Gene Therapy for Inherited Disease
Some diseases are caused by a single broken gene. Gene therapy aims to fix or replace that gene, and the most clinically advanced approach uses genetically modified viruses as delivery trucks. Adeno-associated viruses (AAVs) are small, non-disease-causing viruses that have been engineered to carry therapeutic genes into a patient’s cells. Decades of development have yielded approved products for conditions including spinal muscular atrophy, certain inherited blindness, and hemophilia. Zolgensma, for instance, is a one-time treatment that delivers a working copy of the SMN1 gene to replace the mutated version in babies with spinal muscular atrophy.8Signal Transduction and Targeted Therapy. Viral vector platforms within the gene therapy landscape These viral vector-based gene therapies have produced promising outcomes across cancer, infectious diseases, and single-gene disorders.9PubMed Central. Viral vector-based gene therapies in the clinic
A major area of active research is improving the viral delivery vehicles themselves. Natural AAV capsids (the protein shells that carry the therapeutic gene) have limitations: they may trigger immune responses, get filtered out by the liver before reaching their target tissue, or transduce the wrong cell types. Engineers are now designing novel capsids using a combination of structural analysis, laboratory evolution, and machine learning to create versions with better tissue targeting, lower immune visibility, and higher efficiency.10PubMed Central. Advances in AAV capsid engineering: Integrating rational design, directed evolution and machine learning These improvements matter because a more precise delivery vehicle means lower doses, fewer side effects, and the possibility of treating organs that current vectors reach poorly, like the brain or muscles throughout the body.
CRISPR Gene Editing as Treatment
Gene therapy traditionally adds a working gene without removing the broken one. Gene editing goes further by rewriting the patient’s own DNA. The most dramatic clinical example so far involves sickle cell disease and beta-thalassemia, two blood disorders caused by mutations in hemoglobin genes. In a landmark trial, researchers removed blood stem cells from patients, used CRISPR-Cas9 to edit a specific genetic switch (the BCL11A enhancer) that normally silences fetal hemoglobin production, and infused the edited cells back. More than a year later, both the sickle cell patient and the beta-thalassemia patient showed high levels of editing in their bone marrow, substantial increases in fetal hemoglobin spread across their red blood cells, freedom from transfusions, and, in the sickle cell patient, complete elimination of painful vaso-occlusive crises.11PubMed. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
This work led to the approval of Casgevy (exagamglogene autotemcel), the first CRISPR-based therapy to reach the market. The treatment is complex and demanding on the patient, involving chemotherapy to clear existing bone marrow before the edited cells are returned, but it represents a potential one-time cure for diseases that previously required lifelong transfusions or bone marrow transplants from matched donors. The approach of targeting BCL11A rather than directly correcting the sickle cell mutation was a clever workaround: by reawakening fetal hemoglobin, which naturally compensates for defective adult hemoglobin, the therapy sidesteps the need to fix the original mutation letter by letter.
Cancer Immunotherapy With Engineered Cells
CAR-T cell therapy is one of the most striking examples of GMOs in medicine because the “genetically modified organism” is the patient’s own immune cells. Doctors draw a patient’s T cells (a type of white blood cell), then use a modified virus, typically a lentiviral vector, to insert a gene encoding a chimeric antigen receptor (CAR). This synthetic receptor lets the T cells recognize and attack a specific protein on the surface of cancer cells. The engineered T cells are expanded in the lab and infused back into the patient. Several CAR-T products, including tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta), and brexucabtagene autoleucel (Tecartus), have received FDA and EMA approval for blood cancers, and all rely on retroviral or lentiviral vectors to deliver the CAR gene.12PubMed Central. Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives
The current process is expensive and logistically complicated. Each patient’s cells must be collected, shipped to a manufacturing facility, engineered, grown, tested, and shipped back. Researchers are now exploring whether the engineering step could happen inside the body. In animal studies, an engineered lentiviral vector designed to target only T cells was injected directly into mice bearing human tumors. The vector specifically infected T cells while barely touching other cell types, generated functional CAR-T cells in the animals’ bodies, and controlled tumor growth comparably to conventionally manufactured CAR-T cells.13Scientific Reports. A targeting lentiviral vector for generation of CAR-T cells in vivo If that approach translates to humans, it could turn a weeks-long manufacturing process into something closer to an injection, dramatically expanding access.
Oncolytic Viruses That Hunt Tumors
While some engineered viruses deliver genes, others are designed to kill cancer cells directly. Oncolytic viruses are either naturally occurring or genetically engineered to selectively replicate inside tumor cells while leaving normal tissue alone. As the virus copies itself, it ruptures the cancer cell, releasing new virus particles that infect neighboring tumor cells. This process also spills tumor-specific molecules into the surrounding tissue, effectively flagging the cancer for the patient’s own immune system.14PubMed Central. Oncolytic virus therapy: A new era of cancer treatment at dawn The first oncolytic virus approved in the United States, talimogene laherparepvec (T-VEC), is a genetically modified herpes simplex virus used for advanced melanoma. It was engineered to replicate only in cancer cells and to produce an immune-stimulating molecule that amplifies the body’s antitumor response.
Transplant Organs From Gene-Edited Pigs
The shortage of donor organs kills thousands of people every year. One radical solution is xenotransplantation: transplanting organs from animals, most often pigs, into humans. The problem is that the human immune system violently rejects pig tissue, partly because pig cells carry sugar molecules on their surface that human antibodies immediately attack. Genetic engineering now allows researchers to knock out the pig genes responsible for those sugars and add human genes that help the organ evade immune destruction.15PubMed Central. Genetically engineered pigs for xenotransplantation: Hopes and challenges
A separate safety concern is that pig genomes harbor porcine endogenous retroviruses (PERVs), viral DNA remnants woven into pig chromosomes that could theoretically reactivate and infect human cells. Researchers used CRISPR-Cas9 to inactivate all PERVs in a pig cell line and then cloned live pigs from those edited cells.16PubMed Central. Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9 This addressed one of the longest-standing objections to pig-to-human transplants.17PubMed. Using CRISPR to inactivate endogenous retroviruses in pigs: an important step toward safe xenotransplantation? In recent years, gene-edited pig kidneys and hearts have been transplanted into human patients in closely monitored procedures, with some recipients surviving for months. The technology is still experimental, but it represents a potential answer to organ shortages that no amount of public awareness campaigning has been able to solve.
Transgenic Animals and Plants as Protein Producers
Bacteria and yeast are the workhorse protein factories, but some therapeutic proteins are too complex for microbes to produce correctly. One alternative is transgenic animals, typically goats or rabbits, engineered so that a human protein gene is linked to a milk-production signal. The animal produces the therapeutic protein in its milk, which is then collected and purified. This approach has been used commercially for antithrombin, a blood protein that prevents clotting, produced in the milk of transgenic goats. Advances in genome editing have made it faster and more reliable to generate these animals.18PubMed Central. Production of Recombinant Proteins in the Milk of Transgenic Animals: Current State and Prospects
Plants offer yet another platform. Genetically modified tobacco, lettuce, rice, and other crops have been engineered to produce antibodies, vaccines, and other biopharmaceuticals. The appeal is cost: plant-derived biopharmaceuticals are cheaper to produce and store, easier to scale up, and safer than those derived from animal cell cultures, which carry a small risk of transmitting animal viruses.19PubMed Central. Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants The technology, often called molecular farming, has matured substantially and proved its advantages in safety, speed, and reduced manufacturing costs.20PubMed. Current state-of-the-art in plant-based antibody production systems The COVID-19 pandemic highlighted the potential: a plant-derived COVID vaccine (Covifenz) was authorized in Canada, produced in modified tobacco plants. Still, regulatory hurdles and public perception challenges have slowed broader adoption of plant-made pharmaceuticals.
Engineered Bacteria as Living Medicines and Diagnostics
Beyond producing proteins in a factory, researchers are engineering bacteria to function as living therapeutics that operate inside the body. The FDA has recognized certain microorganisms with therapeutic potential as “live biotherapeutic products,” a regulatory category for engineered or selected bacterial strains designed to treat disease, particularly metabolic conditions, by restoring gut microbiome balance and regulating metabolic functions.21PubMed Central. Live Biotherapeutic Products for Metabolic Diseases: Development Strategies, Challenges, and Future Directions Some engineered bacteria are designed to produce a drug only when they detect a specific disease signal in their environment, creating a “sense and respond” system that conventional drugs cannot match.
On the diagnostic side, researchers have built bacterial biosensors that detect disease biomarkers in patient samples. One team engineered bacteria with programmable receptors that could detect abnormal bile salt levels in blood serum from liver transplant patients, producing a color change visible to the naked eye.22Nature Communications. Programmable receptors enable bacterial biosensors to detect pathological biomarkers in clinical samples A cheap, equipment-free diagnostic like that could be transformative in low-resource healthcare settings where sophisticated lab instruments are unavailable.
Of course, releasing engineered bacteria into patients or the environment raises obvious safety questions. What if the organisms escape their intended context and spread? Synthetic biologists have developed genetic kill switches to address this. In one design, called the “Deadman” switch, the engineered bacterium requires a specific chemical signal to stay alive. Remove that signal, and the circuit activates toxins that destroy the cell. Testing showed that a combinatorial version of this switch killed cells below the limit of detection within six hours.23PubMed Central. “Deadman” and “Passcode” microbial kill switches for bacterial containment These biocontainment systems are not just theoretical precautions; regulators increasingly expect them as part of any application involving engineered organisms released outside a sealed bioreactor.
Genetically Modified Mosquitoes for Disease Prevention
Not all medical GMOs go into your body. Mosquito-borne diseases like dengue, Zika, and malaria kill hundreds of thousands of people annually, and genetic engineering offers new tools for vector control. One approach uses a self-limiting gene: male mosquitoes are engineered so that their offspring die before reaching adulthood. When these males are released into the wild and mate with local females, the next generation collapses. Field trials of the OX513A strain of Aedes aegypti have shown effectiveness at reducing pest mosquito populations in multiple countries.24Psyche: A Journal of Entomology. Self-Limiting OX513A Aedes aegypti Demonstrate Full Susceptibility to Currently Used Insecticidal Chemistries as Compared to Indian Wild-Type Aedes aegypti Other strategies use synthetic biology to make mosquitoes resistant to carrying pathogens like the malaria parasite, so that even if they bite you, they cannot transmit the disease.25PubMed Central. Advances and challenges in synthetic biology for mosquito control These approaches are controversial, and community engagement is critical before any release, but the public health stakes drive continued research.
mRNA Technology and the Expanding Toolkit
The COVID-19 mRNA vaccines from Pfizer-BioNTech and Moderna are sometimes grouped alongside GMO-based medicines, though the distinction matters. The vaccines themselves are synthetic messenger RNA molecules packaged in lipid nanoparticles, not living organisms. However, the underlying science draws on decades of GMO research, including optimization of chemically modified nucleotides to boost protein expression from synthetic mRNA.26PubMed Central. Lipid Nanoparticle-mRNA Formulations for Therapeutic Applications The same lipid nanoparticle-mRNA platform is now being developed for cancer immunotherapy, rare genetic diseases, and even autoimmune conditions. It sits at the intersection of genetic medicine and synthetic chemistry, and its rapid success during the pandemic demonstrated how quickly GMO-adjacent technologies can move from laboratory curiosity to global deployment.
The Cost Problem
Many of these therapies work remarkably well for the patients who can access them, but access is the sticking point. Gene therapies carry sticker prices that can exceed a million dollars per patient. CAR-T cell treatments typically cost several hundred thousand dollars, not counting hospitalization. Even routine biologics like monoclonal antibodies are far more expensive than small-molecule drugs. The challenge of paying for gene therapy has prompted discussion of novel financing strategies, including outcomes-based payment models and policy reform.27PubMed Central. Managing the challenges of paying for gene therapy: strategies for market action and policy reform in the United States The FDA has also worked to streamline the regulatory pathway for gene therapy products, issuing updated guidance in 2020 that reduced testing and follow-up burdens compared to earlier requirements.28PubMed Central. Clinical Development of Gene Therapies: The First Three Decades and Counting
Plant-based and microbial production platforms may eventually help bring costs down for certain biologics, but the most complex therapies, where each patient’s cells are individually engineered, are inherently expensive to manufacture. The tension between therapeutic promise and economic reality is arguably the defining challenge for GMO-based medicine over the next decade. A cure that exists but that only wealthy healthcare systems can afford is, for much of the world’s population, not really a cure at all.